Variation in commercial smoking mixtures containing third-generation synthetic cannabinoids

Drug Testing and Analysis

Volumn 9, Issue 2, 2017, Pages 327-333

  Frinculescu, Anca ^a   Lyall, Catherine L ^b   Ramsey, John ^a   Miserez, Bram ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF BATH   (United Kingdom)

Author keywords

5 F AKB48; 5 F APINACA; 5 F PB 22; 5 F QUPIC; smoking mixtures; synthetic cannabinoids

Indexed keywords

5 F-AKB48; 5 F-APINACA; 5 F-PB-22; 5 F-QUPIC; ACTIVE COMPOUNDS; ACTIVE INGREDIENTS; CANNABINOIDS; SMOKING MIXTURE; SYNTHETIC CANNABINOID; THIRD GENERATION;

COPYRIGHTS;

1 (5 FLUOROPENTYL) 8 QUINOLINYL ESTER 1H INDOL 3 CARBOXYLIC ACID; CANNABINOID; N (ADAMANTAN 1 YL) 1 (5 FLUOROPENTYL) 1H INDAZOLE 3 CARBOXAMIDE; SYNTHETIC CANNABINOID; UNCLASSIFIED DRUG; DESIGNER DRUG;

ARTICLE; CHEMICAL ANALYSIS; CHEMICAL COMPOSITION; PACKAGING; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SMOKING; STANDARDIZATION; CANNABIS SMOKING; CHEMISTRY; HUMAN; MASS FRAGMENTOGRAPHY; MEDICINAL PLANT;

CANNABINOIDS; DESIGNER DRUGS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MARIJUANA SMOKING; PLANTS, MEDICINAL;

EID: 84968538362     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.1975     Document Type: Article

References (38)

1. P. Deluca, Z. Davey, O. Corazza, L. Di Furia, M. Farre, L. H. Flesland, M. Mannonen, A. Majava, T. Peltoniemi, M. Pasinetti, C. Pezzolesi, N. Scherbaum, H. Siemann, A. Skutle, M. Torrens. Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2012, 39, 221.
2. D.M. Lambert (Ed.). Cannabinoids in Nature and Medicines. Helvetica Chimica Acta Verlag, Zürich, 2009.
3. K. A. Seely, P. L. Prather, P. L. James, J. H. Moran. Marijuana-based drugs: innovative therapeutics or designer drugs of abuse? Mol. Interventions. 2011, 11, 36.
4. N. Uchiyama, R. Kikura-Hanajiri, N. Kawahara, Y. Goda. Identification of a cannabimimetic indole as a designer drug in a herbal product. Forensic Toxicol. 2009, 27, 61.
5. V. Auwärter, S. Dresen, W. Weinmann, M. Müller, M. Pütz, N. Ferreirós. Spice and other herbal blends: harmless incense or cannabinoid designer drugs? J. Mass Spectrom. 2009, 44, 832.
6. S. Dresen, N. Fereiros, M. Putz, F. Westphal, R. Zimmermann, V. Auwarter. Monitoring of herbal mixtures potentially containing synthetic cannbinoids as psychoactive compounds. J. Mass Spectrom. 2010, 45, 1186.
7. D. L. Wells, C. A. Ott. The ‘new’ marijuana. Ann. Pharmacother. 2011, 45, 414.
8. European Monitoring Centre for Drugs and Drug Addiction. New Psychoactive Substances in Europe - An Update from the EU Early Warning System (March 2015). Office for Official Publications of the European Communities, Lisbon, 2015.
9. Statutory Instruments. 2013. The Misuse of Drugs Act 1971 (Amendment) Order 2013. Available at: http://www.legislation.gov.uk/uksi/2013/239/pdfs/uksi_20130239_en.pdf [15 January 16].
10. ACMD. 2014. ‘Third generation’ synthetic cannabinoids. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/380161/CannabinoidsReport.pdf [15 January 16].
11. P. I. Dargan, S. Hudson, J. Ramsey, D. M. Wood. The impact of changes in UK classification of the synthetic cannabinoid receptor agonists in ‘Spice’. Int. J. Drug Policy. 2011, 22, 274.
12. K. A. Seely, J. Lapoint, J. H. Moran, L. Fattore. Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2012, 39, 234.
13. K. G. Shanks, G. S. Behonick, T. Dahn, A. Terrell. Identification of novel third-generation synthetic cannabinoids in products by ultra-performance liquid chromatography and time-of-flight mass spectrometry. J. Anal. Toxicol. 2013, 37, 517.
14. N. Uchiyama, R. Kikura-Hanajiri, N. Kawahara, Y. Haishim, Y. Goda. Identification of a cannabinoid analog as a new type of designer drug in a herbal product. Chem. Pharm. Bull. 2009, 57, 439.
15. B. K. Logan, L. E. Reinhold, A. Xu, F. X. Diamond. Identification of synthetic cannabinoids in herbal incense blends in the United States. J. Forensic Sci. 2012, 57, 1168.
16. S. J. Dunham, P. D. Hooker, R. M. Hyde. Identification, extraction and quantification of the synthetic cannabinoid JWH-018 from commercially available herbal marijuana alternatives. Forensic Sci. Int. 2012, 223, 241.
17. G. Merola, Z. Aturki, G. D'Orazio, R. Gottardo, T. Macchia, F. Tagliaroc, S. Fanali. Analysis of synthetic cannabinoids in herbal blends by means of nano-liquid chromatography. J. Pharm. Biomed. Anal. 2012, 71, 45.
18. R. Gottardo, A. Bertaso, J. Pascali, D. Sorio, G. Musile, E. Trapani, C. Seri, G. Serpelloni, F. Tagliaro. Micellar electrokinetic chromatography: A new simple tool for the analysis of synthetic cannabinoids in herbal blends and for the rapid estimation of their log P values. J. Chromatogr. A. 2012, 1267, 198.
19. N. Langer, R. Lindigkeit, H. M. Schiebel, L. Ernst, T. Beuerle. Identification and quantification of synthetic cannabinoids in ‘spice-like’ herbal mixtures: a snapshot of the German situation in the autumn of 2012. Drug Test. Anal. 2013, 6, 59.
20. I. Vardakou, C. Pistos, C. Spiliopoulou. Spice drugs as a new trend: mode of action, identification and legislation. Toxicol. Lett. 2010, 197, 157.
21. H. Choi, H. Sewoong, S. Choe, W. Yang, Y. Park, E. Kim, H. Chung, J. Lee. Simultaneous analysis of synthetic cannabinoids in materials seized during drug trafficking using GC-MS. Anal. Bioanal. Chem. 2013, 405, 3937.
22. B. Moosmann, V. Angerer, V. Auwarter. Inhomogeneity in herbal mixtures: a serious risk for consumers. Forensic Toxicol. 2015, 33, 54.
23. J. Trecki, R. R. Gerona, M. Schwatrz. Synthetic cannbinoid-related illnesses and deaths. New Eng. J. Med. 2015, 372, 103.
24. A. Winstock, M. Lynskey, R. Borschmann, J. Waldron. Risk of emergency medical treatment following consumption of cannabis or synthetic cannabinoids in a large global sample. J. Psychopharmacol. 2015, 29, 698.
25. S. D. Banister, J. Stuart, R. C. Kevin, A. Edington, M. Longworth, S. M. Wilkinson, C. Beinat, A. S. Buchanan, D. E. Hibbs, M. Glass, M. Connor, I. S. McGregor, M. Kassion. Effects of bioisoteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5 F-PB-22, APICA and STS-135. ASC Chem. Neurosci. 2015, 6, 1445.
26. M. B. Gatch, M. J. Forster. Δ9-Tetrahydrocannabinol-like effects of novel synthetic cannabinoids found on the gray market. Behav. Pharmacol. 2015, 26, 460.
27. V. J. Koller, F. Ferk, H. Al-Serori, M. Misik, A. Nersesyan, V. Auwarter, T. Grummt, B. Knasmuller. Genotoxic properties of representatives of alkylindazoles and aminoalkyl-indoles which are consumed as synthetic cannabinoids. Food Chem. Toxicol. 2015, 80, 130.
28. A. Wolhfarth, A. S. Gandhi, S. Pang, M. Zhu, K. B. Scheidweiler, M. A. Huestis. Metabolism of synthetic cannabinoids PB-22 and its 5-fluoro analog, 5 F-PB-22, by human hepatocyte incubation and high-resolution mass spectrometry. Anal. Bioanal. Chem. 2014, 406, 1763.
29. R. Thomsen, L. M. Nielsen, N. B. Holm, H. B. Rasmussen, K. Linnet, the INDICES Consortium. Synthetic cannabimimetic agent metabolised by carboxylesterases. Drug Test. Anal. 2015, 76, 565.
30. G. Behonick, K. G. Shanks, D. J. Firchau, G. Mathur, C. F. Lynch, M. Nashelsky, D. J. Jaskierny, C. Meroueh. Four postmortem case reports with quantitative detection of the synthetic cannabinoid, 5 F-PB-22. J. Anal. Toxicol. 2014, 38, 559.
31. N. B. Holm, A. J. Pedersen, P. W. Dalsgaard, K. Linnet. Metabolites of 5 F-AKB-48, a synthetic cannabinoid receptor agonist, identified in human urine and liver microsomal preparations using liquid chromatography high-resolution mass spectrometry. Drug Test. Anal. 2015, 7, 199.
32. S. Vikingsson, M. Josefsson, H. Green. Identification of AKB-48 and 5 F-AKB-48 metabolites in authentic human urine samples using human liver microsomes and time of flight mass spectrometry. J. Anal. Toxicol. 2015, 39, 426.
33. K. Tsujikawa, T. Yamamoro, K. Kuwayama, T. Kanamori, Y. T. Iwata, H. Inoue. Thermal degradation of a new synthetic cannabinoids QUPIC during analysis by gas chromatography-mass spectrometry. Forensic Toxicol. 2013, 32, 201.
34. Cayman Chemical. 2016. Spectral Library. Available at: https://www.caymanchem.com/app/template/SpectralLibrary.vm [15 January 16].
35. 1H NMR spectroscopy. TRAC-Trend. Anal. Chem. 2012, 35, 5.
36. F. Malz, H. Jancke. Validation of quantitative NMR. J. Pharm. Biomed. Anal. 2005, 38, 813.
37. G. F. Pauli, T. Gödecke, B. U. Jaki, D. C. Lankin. Quantitative 1H NMR: development and potential of an analytical method – an update. J. Nat. Prod. 2012, 75, 834.
38. Report of the Expert Panel. 2014. New Psychoactive Substances review. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/368583/NPSexpertReviewPanelReport.pdf [15 January 2016].